Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lexicon: Outrageous fortune?

Lexicon Genetics Inc. has received some absolution in its controversy with the scientific community, which erupted in the fall after researchers at the Howard Hughes Medical Institute refused to sign the company's material transfer agreement for its OmniBank library of mutant embryonic stem (ES) cells. But at the same time, the company now faces direct competition from academia.

The controversy stemmed

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers